Histone deacetylase inhibitors in clinical development

Expert Opinion on Investigational Drugs

Volumn 13, Issue 1, 2004, Pages 21-38

  Rosato, Roberto R ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Clinical development; Differentiation; HDAC inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; DEPSIPEPTIDE; DEXTRAN DERIVATIVE; FLAVOPIRIDOL; FR 901228; GEMCITABINE; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHENYLACETIC ACID; PIVALOYLOXYMETHYL BUTYRATE; PLATINUM; PYROXAMIDE; RETINOIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIDE INFRA; VORINOSTAT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CARDIOTOXICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG ACETYLATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; MOUSE; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642555570     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.1.21     Document Type: Review

References (195)

1. VIGUSHIN DM, COOMBES RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 13:1-13.
2. MELNICK A, LICHT JD: Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. (2002) 9:322-332.
3. MARKS PA, RIFKIND RA, RICHON VM et al.: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer (2001) 1:194-202.
4. KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trials. Expert. Opin. Investig. Drugs (2002) 11:1695-1713.
5. URNOV FD, WOLFFE A: Chromatin organization and human disease. Emer. Ther. Targets (2002) 4:665-685.
6. MAHLKNECHT U, HOELZER D: Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. (2000) 6:623-644.
7. TIMMERMANN S, LEHRMANN H, POLESSKAYA A, HAREL-BELLAN A: Histone acetylation and disease. Cell Mol. Life Sci. (2001) 58:728-736.
8. CRESS WD, SETO E: Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. (2000) 184:1-16.
9. JOHNSTONE RW, LICHT JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 4:13-18.
10. STRAHL BD, ALLIS CD: The language of covalent histone modifications. Nature (2000) 403:41-45.
11. GRAY SG, TEH BT: Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr. Mol. Med. (2001) 1:401-429.
12. DE RUIJTER AJ, VAN GENNIP AH, CARON HN et al.: Histone deacetylases: characterisation of the classical HDAC family. Biochem. J. (2003) 370:737-749.
13. GREGORY PD, WAGNER K, HORZ W: Histone acetylation and chromatin remodeling. Exp. Cell Res. (2001) 265:195-202.
14. GRAY SG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell Res. (2001) 262:75-83.
15. ROTH SY, DENU JM, ALLIS CD: Histone acetyltransferases. Ann. Rev. Biochem. (2001) 70:81-120.
16. WADE PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. (2001) 10:693-698.
17. FORSBERG EC, BRESNICK EH: Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays (2001) 23:820-830.
18. WANG C, FU M, MANI S et al.: Histone acetylation and the cell-cycle in cancer. Front. Biosci. (2001) 6:D610-D629.
19. CANDIDO EP, REEVES R, DAVIE JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell (1978) 14:105-113.
20. COUSENS LS, GALLWITZ D, ALBERTS BM: Different accessibilities in chromatin to histone acetylase. J. Biol. Chem. (1979) 254:1716-1723.
21. KRUH J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem. (1982) 42:65-82.
22. TROCK B, LANZA E, GREENWALD P: Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. J. Natl. Cancer Inst. (1990) 82:650-661.
23. ARCHER SY, HODIN RA: Histone acetylation and cancer. Curr. Opin. Genet. Dev. (1999) 9:171-174.
24. MEDINA V, AFONSO JJ, ALVAREZ-ARGUELLES H et al.: Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. J. Parenter. Enteral Nutr. (1998) 22:14-17.
25. ROSATO RR, WANG Z, GOPALKRISHNAN RV et al.: Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. (2001) 19:181-191.
26. DAVIE JR: Inhibition of histone deacetylase activity by butyrate. J. Nutr. (2003) 133:2485S-2493S.
27. NEWMARK HL, YOUNG CW: Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell Biochem. Suppl. (1995) 22:247-253.
28. NUDELMAN A, GNIZI E, KATZ Y et al.: Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur. J. Med. Chem. (2001) 36:63-74.
29. NUDELMAN A, REPHAELI A: Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem. (2000) 43:2962-2966.
30. ZIMRA Y, WASSERMAN L, MARON L et al.: Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J. Cancer Res. Clin. Oncol. (1997) 123:152-160.
31. AVIRAM A, REPHAELI A, SHAKLAI M et al.: Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. J. Cancer Res. Clin. Oncol. (1997) 123:267-271.
32. BATOVA A, SHAO LE, DICCIANNI MB et al.: The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood (2002) 100:3319-3324.
33. SIU LL, VON HOFF DD, REPHAELI A et al.: Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest. New Drugs (1998) 16:113-119.
34. ZIMRA Y, MARON L, SHAKLAI M et al.: Pivaloyloxymehtyl butyrate (AN-9) exhibits higher anticancer activity than butyric acid (BA): it penetrates faster than the acid and induces apoptosis in HL60 cells. Proc. Am. Soc. Hematol. (1994):579a (Abstract).
35. PATNAIK A, ROWINSKY EK, VILLALONA MA et al.: A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. (2002) 8:2142-2148.
36. HARRISON LE, WOJCIECHOWICZ DC, BRENNAN MF, PATY PB: Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery (1998) 124:541-550.
37. DI BENEDETTO M, KOURBALI Y, STARZEC A et al.: Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice. Br. J. Cancer (2001) 85:917-923.
38. CHANG SM, KUHN JG, ROBINS HI et al.: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol. (1999) 17:984-990.
39. GORE SD, WENG LJ, ZHAI S et al.: Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. (2001) 7:2330-2339.
40. GILBERT J, BAKER SD, BOWLING MK et al.: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. (2001) 7:2292-2300.
41. DIGIUSEPPE JA, WENG LJ, YU KH et al.: Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (1999) 13:1243-1253.
42. DOVER GJ, BRUSILOW S, SAMID D: Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N. Engl. J. Med. (1992) 327:569-570.
43. CALVARUSO G, CARABILLO M, GIULIANO M et al.: Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int. J. Oncol. (2001) 18:1233-1237.
44. NG AY, BALES W, VELTRI RW: Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines. Anal. Quant. Cytol. Histol. (2000) 22:45-54.
45. WANG QM, FEINMAN R, KASHANCHI F et al.: Changes in E2F binding after phenylbutyrate-induced differentiation of Caco-2 colon cancer cells. Clin. Cancer Res. (2000) 6:2951-2958.
46. GOH M, CHEN F, PAULSEN MT et al.: Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia. (2001) 3:331-338.
47. CLARKE KO, LUDEMAN SM, SPRINGER JB et al.: Exposure to a deuterated analogue of phenylbutyrate retards S-phase progression in HT-29 colon cancer cells. J. Pharm. Sci. (2002) 91:1054-1064.
48. MCGRATH-MORROW SA, STAHL JL: G(1) Phase growth arrest and induction of p21 (Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate. J. Pharmacol. Exp. Ther. (2000) 294:941-947.
49. DYER ES, PAULSEN MT, MARKWART SM et al.: Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int. J. Cancer (2002) 101:496-499.
50. CARDUCCI MA, GILBERT J, BOWLING MK et al.: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion Schedule. Clin. Cancer Res. (2001) 7:3047-3055.
51. GORE SD, WENG LJ, FIGG WD et al.: Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute mycloid leukemia. Clin. Cancer Res. (2002) 8:963-970.
52. YU KH, WENG LJ, FU S et al.: Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia (1999) 13:1258-1265.
53. GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. (2001) 20:6969-6978.
54. GRAZIANI G, TENTORI L, PORTARENA I et al.: Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology (2003) 144:2822-2828.
55. LUGER SM, BAGG A, STADTMAUER EA et al.: Pilot study of valproic acid in patients with myelodysplasia.. Proc. Am. Soc. Hematology (2003):5057 (Abstract).
56. PRAKASH S, FOSTER BJ, MEYER M et al.: Chronic oral administration of CI-994: a phase 1 study. Invest. New Drugs (2001) 19:1-11.
57. KRAKER AJ, MIZZEN CA, HARTL BG et al.: Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol. Cancer Ther. (2003) 2:401-408.
58. WOZNIAK A, O'SHAUGHNESSY J, FIORICA J, GROVE W. Phase II trial of CI-994 in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Onc. (1999):1878 (Abstract).
59. O'SHAUGHNESSY J, FLAHERTY L, FIORICA J, GROVE W: Phase II trial of CI-994 in patients with metastic renal cell carcinoma. Proc. Am. Soc. Clin. Onc. (1999):1346 (Abstract).
60. KIMMEL KA, KINDLER HL, JANISCH S et al.: Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Onc. (2001):345 (Abstract).
61. OLIVARES J, WILLIAMS A, OLSON S et al.: Phase I pharmacokinetic study of CI-994 in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Onc. (2000:346 (Abstract).
62. NEMUNAITIS JJ, ORR D, EAGER R et al.: Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. (2003) 9:58-66.
63. SUZUKI T, ANDO T, TSUCHIYA K et al.: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. (1999) 42:3001-3003.
64. SAITO A, YAMASHITA T, MARIKO Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA (1999) 96:4592-4597.
65. LEE BI, PARK SH, KIM JW et al.: MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res (2001) 61:931-934.
66. JABOIN J, WILD J, HAMIDI H et al.: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. (2002) 62:6108-6115.
67. ROSATO RR, ALMENARA JA, GRANT S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. (2003) 63:3637-3645.
68. UEDA H, NAKAJIMA H, HORI Y et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) (1994) 47:301-310.
69. UEDA H, MANDA T, MATSUMOTO S et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaccum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) (1994) 47:315-323.
70. SASAKAWA Y, NAOE Y, INOUE T et al.: Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. (2002) 64:1079-1090.
71. BYRD JC, SHINN C, RAVI R et al.: Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood (1999) 94:1401-1408.
72. KWON HJ, KIM MS, KIM MJ et al.: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer (2002) 97:290-296.
73. YU X, GUO ZS, MARCU MG et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. (2002) 94:504-513.
74. SANDOR V, BAKKE S, ROBEY RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. (2002) 8:718-728.
75. MARSHALL JL, RIZVI N, KAUH J et al.: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. (2002) 2:325-332.
76. PIEKARZ RL, ROBEY R, SANDOR V et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 98:2865-2868.
77. VIGUSHIN DM: FR-901228 Fujisawa/National Cancer Institute. Curr. Opin. Investig. Drugs (2002) 3:1396-1402.
78. DARKIN-RATTRAY SJ, GURNETT AM, MYERS RW et al.: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA (1996) 93:13143-13147.
79. HAN JW, AHN SH, PARK SH et al.: Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. (2000) 60:6068-6074.
80. KIM MS, SON MW, KIM WB et al.: Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. (2000) 157:23-30.
81. WITT O, MONKEMEYER S, ROENNDAHL G et al.: Induction of fetal hemoglobin expression by the histone-deacetylase inhibitor apicidin. Blood (2002) 101:2001-2007.
82. WITT O, MONKEMEYER S, KANBACH K, PEKRUN A: Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. Am. J. Hematol. (2002) 71:45-46.
83. YOSHIDA M, KIJIMA M, AKITA M, BEPPU T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. (1990) 265:17174-17179.
84. YOSHIDA M, NOMURA S, BEPPU T: Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. (1987) 47:3688-3691.
85. YAMASHITA Y, SHIMADA M, HARIMOTO N et al.: Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer (2003) 103:572-576.
86. BUTLER LM, WEBB Y, AGUS DB et al.: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. (2001) 7:962-970.
87. RICHON VM, WEBB Y, MERGER R et al.: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA (1996) 93:5705-5708.
88. COFFEY DC, KUTKO MC, GLICK RD et al.: Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol. (2000) 35:577-581.
89. MUNSTER PN, TROSO-SANDOVAL T, ROSEN N et al.: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. (2001) 61:8492-8497.
90. VRANA JA, DECKER RH, JOHNSON CR et al.: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene (1999) 18:7016-7025.
91. HUANG L, PARDEE AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. (2000) 6:849-866.
92. BUTLER LM, AGUS DB, SCHER HI et al.: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. (2000) 60:5165-5170.
93. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA (2000) 97:10014-10019.
94. BUTLER LM, ZHOU X, XU WS et al.: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA (2002) 99:11700-11705.
95. CASTRO-GALACHE MD, FERRAGUT JA, BARBERA VM et al.: Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int. J. Cancer (2003) 104:579-586.
96. RUEFLI AA, AUSSERLECHNER MJ, BERNHARD D et al.: The histone deacetylase inhibitor and chemotherapeutic agent suberoyfanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA (2001) 98:10833-10838.
97. COHEN LA, MARKS PA, RIFKIND RA et al.: Suberoylanilide hydroxamic acid (SARA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. (2002) 22:1497-1504.
98. DESAI D, DAS A, COHEN L et al.: Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. (2003) 23:499-503.
99. KELLY WK, RICHON VM, O'CONNOR O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 9:3578-3588.
100. CATLEY L, WEISBERG E, TAI Yr et al.: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood (2003) 102:2615-2622.
101. NIMMANAPALLI R, FUINO L, BALI P et al.: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukernia-blast crisis cells. Cancer Res (2003) 63:5126-5135.
102. QIU L, KELSO MJ, HANSEN C et al.: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer (1999) 80:1252-1258.
103. QIU L, BURGESS A, FAIRLIE DP et al.: Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol Cell (2000) 11:2069-2083.
104. WARRENER R, BEAMISH H, BURGESS A et al.: Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. (2003) 17:1550-1552.
105. VAN LINT C, EMILLANI S, VERDIN E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. (1996) 5:245-253.
106. LEE H, LEE S, BAEK M et al.: Expression profile analysis of trichostatin A in human gastric cancer cells. Biotech. Lett. (2002) 24:377-381.
107. GLASER KB, STAVER MJ, WARING JF et al.: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. (2003) 2:151-163.
108. BREHM A, MISKA EA, MCCANCE DJ et al.: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391:597-601.
109. MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEVA I et al.: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 391:601-605.
110. BOUZAHZAH B, FU M, IAVARONE A et al.: Transforming growth factor-beta1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo. Cancer Res. (2000) 60:4531-4537.
111. BLAGOSKLONNY MV, ROBEY R, SACKETT DL et al.: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. (2002) 1:937-941.
112. LALLEMAND F, COURELLEAU D, BUQUET-FAGOT C et al.: Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Exp. Cell Res. (1999) 247:432-440.
113. EL DEIRY WS, TOKINO T, VELCULESCU VE et al.: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75:817-825.
114. MAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther. (2002) 1:253-266.
115. DAI Y, RAHMANI M, GRANT S: An Intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle (2003) 2:467-472.
116. VON HAEFEN C, WIEDER T, ESSMANN F et al.: Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene (2003) 22:2236-2247.
117. KWON SH, AHN SH, KIM YK et al.: Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Eas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. (2002) 277:2073-2080.
118. PEART MJ, TAINTON KM, RUEFLI AA et al.: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. (2003) 63:4460-4471.
119. HENDERSON C, MIZZAU M, PARONI G et al.: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. (2003) 278:12579-12589.
120. ZHANG Y, FUJITA N, TSURUO T: Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene (1999) 18:1131-1138.
121. BISSONNETTE N, HUNTING DJ: p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene (1998) 16:3461-3469.
122. BURGESS AJ, PAVEY S, WARRENER R et al.: Up-regulation of p21 (WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. (2001) 60:828-837.
123. KIM DK, CHO ES, LEE SJ, UM HD: Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas. Biochem. Biophys. Res. Commun. (2001) 289:34-38.
124. SUZUKI A, TSUTOMI Y, AKAHANE K et al.: Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene (1998) 17:931-939.
125. MANDAL M, KUMAR R: Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ. (1996) 7:311-318.
126. HAGUE A, DIAZ GD, HICKS DJ et al.: bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int. J. Cancer (1997) 72:898-905.
127. SAWA H, MURAKAMI H, OHSHIMA Y et al.: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. (2001) 18:109-114.
128. CAO XY, MOHUIDDIN I, ECE F et al.: Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol. (2001) 25:562-568.
129. ARON JL,PARTHUN MR, MARCUCCI G et al.: Depsipeptide (FR901228) induces histone acetylation and inhibition of historic deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood (2003) 102:652-658.
130. KIM MS, KWON HJ, LEE YM et al.: Histone deacetylases induce angiogenesis by negative regulatIon of tumor suppressor genes. Nat. Med. (2001) 7:437-443.
131. SASAKAWA Y, NAOE Y, NOTO T et al.: Antitumor efficacy of FK228, a novel historic deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. (2003) 66:897-906.
132. MIE LY, KIM SH, KIM HS et al.: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. (2003) 300:241-246.
133. SAWA H, MURAKAMI H, OHSHIMA Y et al.: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. (2002) 19:77-81.
134. LIU IT, CHANG HC, CHIANG LC, HUNG WC: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. (2003) 63:3069-3072.
135. YU C, RAHMANI M, ALMENARA J et al.: Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res (2003) 63:2118-2126.
136. YU C, RAHMANI M, CONRAD D et al.: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood (2003) 102:3765-3774.
137. NIMMANAPALLI R, FUINO L, STOBAUGH C et al.: Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood (2003) 101:3236-3239.
138. MOMPARLER RL, BOVENZI V: DNA methylation and cancer. J. Cell Physiol. (2000) 183:145-154.
139. JONES PA, BAYLIN SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. (2002) 3:415-428.
140. KARPF AR, JONES DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene (2002) 21:5496-5503.
141. APARICIO A, WEBER JS: Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs (2002) 3:627-633.
142. ZHU WG, OTTERSON GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents (2003) 3:187-199.
143. CAMERON EE, BACHMAN KE, MYORANEN S et al.: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. (1999) 21:103-107.
144. MIELNICKI LM, YING AM, HEAD KL et al.: Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp. Cell Res. (1999) 249:161-176.
145. PRIMEAU M, GAGNON J, MOMPARLER RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer (2003) 103:177-184.
146. FUJII S, LUO RZ, YUAN J et al.: Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased historic H3 lysine 9 methylation. Hum. Mol. Genet. (2003) 12:1791-1800.
147. YUAN J, LUO RZ, FUJII S et al.: Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res (2003) 63:4174-4180.
148. ZHU WG, LAKSHMANAN RR, BEAL MD, OTTERSON GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. (2001) 61:1327-1333.
149. DU HL, QI Y, SHI YJ et al.: [Apoptosis and re-expression of p16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent]. Ai. Zheng. (2002) 21:1057-1061.
150. FREYTAG SO: Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. Mol. Cell Biol. (1988) 8:1614-1624.
151. VAZIRI C, STICE L, FALLER DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Diffir. (1998) 9:465-474.
152. CARTEE L, WANG Z, DECKER RH et al.: The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human mycloid leukemia cells. Cancer Res. (2001) 61:2583-2591.
153. ALMENARA J, ROSATO R, GRANT S: Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia (2002) 16:1331-1343.
154. NGUYEN DM, SCHRUMP WD, TSAI WS et al.: Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J. Thorac. Cardiovasc. Surg. (2003) 125:1132-1142.
155. CHAO SH, PRICE DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. (2001) 276:31793-31799.
156. WANG HK: Flavopiridol. National Cancer Institute. Curr. Opin. Investig. Drugs (2001) 2:1149-1155.
157. THOMAS JP, TUTSCH KD, CLEARY JF et al.: Phase I clinical and pharmacokinetic trial of the cydin-dependent kinase inhibitor flavopiridol. Cancer Chemother. Pharmacol. (2002) 50:465-472.
158. KOUROUKIS CT, BELCH A, CRUMP M et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin Oncol. (2003) 21:1740-1745.
159. NAGY L, KAO HY, CHAKRAVARTI D et al.: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 89:373-380.
160. MATTHAY KK, VILLABLANCA JG, SEEGER RC et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. (1999) 341:1165-1173.
161. COFFEY DC, KUTKO MC, GLICK RD et al.: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. (2001) 61:3591-3594.
162. PILI R, KRUSZEWSKI MP, HAGER BW et al.: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. (2001) 61:1477-1485.
163. HE LZ, TOLENTINO T, GRAYSON P et al.: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. (2001) 108:1321-1330.
164. DEGOS L, DOMBRET H, CHOMIENNE C et al.: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blmd (1995) 85:2643-2653.
165. TALLMAN MS: Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia (1998) 12(Suppl 1):S37-S40.
166. JING Y, XIA L, WAXMAN S: Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood (2002) 100:1008-1013.
167. KITAMURA K, HOSHI S, KOIKE M et al.: Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. (2000) 108:696-702.
168. KOSUGI H, ITO M, YAMAMOTO Y et al.: In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn. J. Cancer Res. (2001) 92:529-536.
169. WARRELL RP, JR., HE LZ, RICHON V et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (1998) 90:1621-1625.
170. ZHOU DC, KIM SH, DING W et al.: Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood (2002) 99:1356-1363.
171. RAHMANI M, DAI Y, GRANT S: The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate
172. HERNANDEZ A, THOMAS R, SMITH F et al.: Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery (2001) 130:265-272.
173. INOUE H, SHIRAKI K, OHMORI S et al.: Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. (2002) 9:521-525.
174. ROSATO RR, ALMENARA JA, DAI Y, GRANT S: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and TRAIL synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. (2004) (In press).
175. BERNHARD D, SKVORTSOV S, TINHOFER I et al.: Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death. Differ. (2001) 8:1014-1021.
176. RAHMANI M, YU C, REESE E et al.: Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene (2003) 22:6231-6242.
177. RAHMANI M, YU C, DAI Y et al.: Co-administration of the heat shock protein 90 antagonist 17-AAG with SARA or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. (2004) (In press).
178. MAGGIO SC, ROSATO RR, KRAMER L et al.: The histone deacetylase inhibitor MS-275 interacts synergistically with Fludarabine to induce apoptosis in human leukemia cells. Cancer Res. (2004) (In press).
179. PITTI RM, MARSTERS SA, RUPPERT S et al.: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol Chem. (1996) 271:12687-12690.
180. HARA I, MIYAKE H, HARA S et al.: Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int. J. Oncol. (2000) 17:1213-1218.
181. SAVAGE DG, ANTMAN KH: Imatinib mesylate--a new oral targeted therapy. N. Engl. J. Med. (2002) 346:683-693.
182. CARROLL M, OHNO-JONES S, TAMURA S et al.: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 90:4947-4952.
183. DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2:561-566.
184. DAN S, NAITO M, TSURUO T: Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ. (1998) 5:710-715.
185. WANG Q, LI N, WANG X et al.: Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res. (2002) 8:1940-1947.
186. NECKERS L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. (2002) 8:S55-S61.
187. ALMOND JB, COHEN GM: The proteasome: a novel target for cancer chemotherapy. Leukemia (2002) 16:433-443.
188. ZAVRSKI I, NAUJOKAT C, NIEMOLLER K et al.: Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow mycloma cells irrespective of chromosome 13 deletion. J. Cancer Res. Clin. Oncol. (2003) 129:383-391.
189. NAUJOKAT C, SEZER O, ZINKE H et al.: Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur. J. Haematol. (2000) 65:221-236.
190. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin Oncol. (2002) 20:4420-4427.
191. MEISLER AI: Bortezomib in multiple myeloma. N. Engl. J. Med. (2003) 349:1287-1288.
192. GIULIANO M, LAURICELLA M, CALVARUSO G et al.: The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res. (1999) 59:5586-5595.
193. WITZIG TE, TIMM M, STENSON M et al.: Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res. (2000) 6:681-692.
194. KURZ EU, WILSON SE, LEADER KB et al.: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol. Cancer Ther. (2001) 1:121-131.
195. KIM MS, BLAKE M, BAEK JH et al.: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. (2003) 63:7291-7300.